<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">MD</journal-id><journal-title-group><journal-title>Medical  Diagnosis</journal-title></journal-title-group><issn pub-type="epub">2164-540X</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/MD.2020.103028</article-id><article-id pub-id-type="publisher-id">MD-37930</article-id><article-categories><subj-group subj-group-type="heading"><subject>MD20200300000_51971028.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  托伐普坦治疗联合人血白蛋白肝硬化顽固性腹水的临床观察
  Clinical Observation of Tolvaptan in Combination with Human Albumin in Treating Refractory Ascites Due to Liver Cirrhosis
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>潘</surname><given-names>月飞</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>雪省</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>乔</surname><given-names>富平</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>中国人民解放军陆军第81集团军医院疾病预防控制科，河北 张家口</addr-line></aff><aff id="aff2"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>09</month><year>2020</year></pub-date><volume>10</volume><issue>03</issue><fpage>173</fpage><lpage>176</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  目的：观察托伐普坦联合人血白蛋白在治疗肝硬化顽固性腹水中的作用。方法：选取我院2019年1月至2020年1月收治的80例肝硬化顽固性腹水患者为研究对象，随机分为实验组与对照组两组，每组40例，对照组给予限钠、常规利尿、输人血白蛋白等基础治疗，观察组在对照组基础上加用托伐普坦治疗，对比两组患者治疗前后血钠、尿量、腹围的变化水平。结果：治疗组的血钠、腹围、尿量与对照组的差别具有统计学意义(P &lt; 0.05)，而不良反应差别无明显统计学意义(P &gt; 0.05)。结论：应用托伐普坦联合人血白蛋白治疗肝硬化顽固性腹水，比单纯应用限钠、利尿、输人血白蛋白等治疗措施相比，效果更明显，具有重要临床意义。&lt;br/&gt;Objective: To observe the effect of tolvaptan combined with human blood albumin in the treatment of refractory ascites due to cirrhosis. Methods: We Selected 80 cases of liver cirrhosis patients with refractory ascites from our hospital between January 2019 and January 2020 as the research object; then the patients were randomly divided into experimental and control group, and each group had 40 cases. The control group was given sodium limit and conventional foundation treatment such as diuresis, intravenous drip of human albumin protein, but the observation group was not only given treatment as the control group had, but also combined with simvastatin treatment. Consequently, we compared the two groups of patients’ levels of blood sodium, urine and waistline after treatment. Results: The differences of blood sodium, abdominal circumference and urine volume between the treatment group and the control group were statistically significant (P &lt; 0.05), while the differences of adverse reactions had no significance. Conclusion: Compared with sodium restriction, diuresis and human albumin alone, torvartan combined with human albumin in the treatment of refractory ascites due to cirrhosis has more obvious effect and important clinical significance.
 
</p></abstract><kwd-group><kwd>托伐普坦，人血白蛋白，肝硬化，顽固性腹水，临床观察, Tolvaptan</kwd><kwd> Serum Albumin</kwd><kwd> Liver Cirrhosis</kwd><kwd> Refractory Ascites</kwd><kwd> Clinical Observation</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：观察托伐普坦联合人血白蛋白在治疗肝硬化顽固性腹水中的作用。方法：选取我院2019年1月至2020年1月收治的80例肝硬化顽固性腹水患者为研究对象，随机分为实验组与对照组两组，每组40例，对照组给予限钠、常规利尿、输人血白蛋白等基础治疗，观察组在对照组基础上加用托伐普坦治疗，对比两组患者治疗前后血钠、尿量、腹围的变化水平。结果：治疗组的血钠、腹围、尿量与对照组的差别具有统计学意义(P &lt; 0.05)，而不良反应差别无明显统计学意义(P &gt; 0.05)。结论：应用托伐普坦联合人血白蛋白治疗肝硬化顽固性腹水，比单纯应用限钠、利尿、输人血白蛋白等治疗措施相比，效果更明显，具有重要临床意义。</p></sec><sec id="s2"><title>关键词</title><p>托伐普坦，人血白蛋白，肝硬化，顽固性腹水，临床观察</p></sec><sec id="s3"><title>Clinical Observation of Tolvaptan in Combination with Human Albumin in Treating Refractory Ascites Due to Liver Cirrhosis</title><p>Yuefei Pan, Xuexing Wang, Fuping Qiao</p><p>Disease Prevention and Control Section, Army 81st Group Military Hospital, Zhangjiakou Hebei</p><p><img src="//html.hanspub.org/file/17-2170252x4_hanspub.png" /></p><p>Received: Sep. 7<sup>th</sup>, 2020; accepted: Sep. 21<sup>st</sup>, 2020; published: Sep. 28<sup>th</sup>, 2020</p><p><img src="//html.hanspub.org/file/17-2170252x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To observe the effect of tolvaptan combined with human blood albumin in the treatment of refractory ascites due to cirrhosis. Methods: We Selected 80 cases of liver cirrhosis patients with refractory ascites from our hospital between January 2019 and January 2020 as the research object; then the patients were randomly divided into experimental and control group, and each group had 40 cases. The control group was given sodium limit and conventional foundation treatment such as diuresis, intravenous drip of human albumin protein, but the observation group was not only given treatment as the control group had, but also combined with simvastatin treatment. Consequently, we compared the two groups of patients’ levels of blood sodium, urine and waistline after treatment. Results: The differences of blood sodium, abdominal circumference and urine volume between the treatment group and the control group were statistically significant (P &lt; 0.05), while the differences of adverse reactions had no significance. Conclusion: Compared with sodium restriction, diuresis and human albumin alone, torvartan combined with human albumin in the treatment of refractory ascites due to cirrhosis has more obvious effect and important clinical significance.</p><p>Keywords:Tolvaptan, Serum Albumin, Liver Cirrhosis, Refractory Ascites, Clinical Observation</p><disp-formula id="hanspub.37930-formula16"><graphic xlink:href="//html.hanspub.org/file/17-2170252x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/17-2170252x7_hanspub.png" /> <img src="//html.hanspub.org/file/17-2170252x8_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>腹水是肝硬化患者临床最常见的并发症之一，而顽固性腹水是指通过应用最大剂量利尿剂(螺内酯400 mg/d，呋塞米160 mg/d)和限钠饮食(&lt;90 mmol/d)，治疗至少1周后仍没有应答的腹水。肝硬化顽固性腹水一旦发生，往往预示预后不佳，肝性脑病的发生率及短期死亡率均明显升高，治疗难度大。托伐普坦作为一种新型血管加压素V2受体拮抗剂，以通过排水保钠等作用来促进自由水的排出，从而提升血钠水平，增加患者尿量，减轻腹水与体重。人血白蛋白在人体内通过提高血浆胶体渗透压，减少腹水的产生，目前已在临床上广泛应用 [<xref ref-type="bibr" rid="hanspub.37930-ref1">1</xref>]。本研究通过观察托伐普坦联合人血白蛋白对肝硬化难治性腹水的治疗，取得了满意效果，具有一定的临床应用前景，本研究已获得医院伦理学会批准。</p></sec><sec id="s6"><title>2. 资料与方法</title><p>基本资料。研究对象均来自于陆军第81集团军医院2019年1月至2020年1月收治的80例肝硬化顽固性腹水患者。将80例患者随机分为实验组和对照组，其中实验组40人，对照组40人，性别、年龄无统计学差异(P &gt; 0.05)。</p><sec id="s6_1"><title>2.1. 纳入及排除标准</title><p>入选标准：肝硬化失代偿期患者的诊断标准依据2018年《肝硬化腹水及相关并发症的诊疗指南》，难治性腹水的定义为：认为螺内酯160 mg/d联合呋塞米80 mg/d治疗至少１周无应答可诊断顽固型腹 [<xref ref-type="bibr" rid="hanspub.37930-ref2">2</xref>]。排除标准：除外合并严重的心肾功能衰竭、颅脑或血液系统疾病以及有严重营养不良性水肿患者，以及对托伐普坦过敏者。</p></sec><sec id="s6_2"><title>2.2. 治疗方法</title><p>对照组给予利尿剂呋塞米(北京太洋药业有限公司，批准文号国药准字H11020844)每日80 mg口服，螺内酯(国药集团武汉中联四药药业有限公司，国药准字H4202034)每日100 mg口服，所有研究对象均限制钠盐摄人(&lt;6 g/d)、间断输注白蛋白(20~25 g/d)的基础上，给予托伐普坦15 mg/d口服，据血钠浓度可适当加量(15~60 mg/d)，持续服用5~14 d后停药，并随访1个月。观察时点及指标：比较治疗后患者的不同时间点血钠、腹围、体重水平。</p><p>1.3统计学分析采用SPSS 19．0统计软件包进行分析。计量资料均以均数 &#177; 标准差(z &#177; s)描述，采用t检验。计数资料用率(%)表示，采用x<sup>2</sup>检验，P &lt; 0.05表示差异有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><p>1) 比较两组患者治疗前后血钠、腹围及尿量水平，血钠测量采用酶联免疫吸附试验法，腹围采用卷尺测量绕脐一周的腹部周长，尿量利用量杯测量各时间点24小时内的尿液总体积。见表1。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> The change of serum sodium, abdominal circumference and body weight before and after treatment with Tolvaptan in combination with human albumi</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >时间</th><th align="center" valign="middle"  colspan="2"  >血钠(mmol/L)</th><th align="center" valign="middle"  rowspan="2"  >P</th><th align="center" valign="middle"  colspan="2"  >腹围(cm)</th><th align="center" valign="middle"  rowspan="2"  >P</th><th align="center" valign="middle"  colspan="2"  >尿量(ml)</th><th align="center" valign="middle"  rowspan="2"  >P</th></tr></thead><tr><td align="center" valign="middle" >实验组n = 40</td><td align="center" valign="middle" >对照组 n = 40</td><td align="center" valign="middle" >实验组n = 40</td><td align="center" valign="middle" >对照组 n = 40</td><td align="center" valign="middle" >实验组 n = 40</td><td align="center" valign="middle" >对照组 n = 40</td></tr><tr><td align="center" valign="middle" >0</td><td align="center" valign="middle" >126 &#177; 5.5</td><td align="center" valign="middle" >127 &#177; 6.3</td><td align="center" valign="middle" >0.5</td><td align="center" valign="middle" >90 &#177; 22.3</td><td align="center" valign="middle" >89 &#177; 21.5</td><td align="center" valign="middle" >0.6</td><td align="center" valign="middle" >623 &#177; 300</td><td align="center" valign="middle" >625 &#177; 303</td><td align="center" valign="middle" >0.7</td></tr><tr><td align="center" valign="middle" >7 d</td><td align="center" valign="middle" >128 &#177; 3.6</td><td align="center" valign="middle" >127 &#177; 4.7</td><td align="center" valign="middle" >0.2</td><td align="center" valign="middle" >87 &#177; 12.4</td><td align="center" valign="middle" >88 &#177; 20.6</td><td align="center" valign="middle" >0.5</td><td align="center" valign="middle" >1100 &#177; 210</td><td align="center" valign="middle" >810 &#177; 145</td><td align="center" valign="middle" >0.3</td></tr><tr><td align="center" valign="middle" >14 d</td><td align="center" valign="middle" >133 &#177; 5.8<sup>*∆ </sup></td><td align="center" valign="middle" >129 &#177; 3.9</td><td align="center" valign="middle" >0.02</td><td align="center" valign="middle" >85 &#177; 12.8<sup>*∆ </sup></td><td align="center" valign="middle" >87 &#177; 21.7<sup> </sup></td><td align="center" valign="middle" >0.03<sup> </sup></td><td align="center" valign="middle" >1400 &#177; 238<sup>*∆ </sup></td><td align="center" valign="middle" >920 &#177; 180</td><td align="center" valign="middle" >0.04</td></tr><tr><td align="center" valign="middle" >30 d</td><td align="center" valign="middle" >136 &#177; 5.7<sup>*∆ </sup></td><td align="center" valign="middle" >130 &#177; 4.2</td><td align="center" valign="middle" >0.01</td><td align="center" valign="middle" >82 &#177; 15.4<sup>*∆ </sup></td><td align="center" valign="middle" >86 &#177; 17.5<sup> </sup></td><td align="center" valign="middle" >0.005<sup> </sup></td><td align="center" valign="middle" >1680 &#177; 326<sup>*∆ </sup></td><td align="center" valign="middle" >950 &#177; 240</td><td align="center" valign="middle" >0.006</td></tr></tbody></table></table-wrap><p>表1. 托伐普坦联合白蛋白治疗前后患者血钠、腹围、尿量的变化</p><p><sup>Δ</sup>P &lt; 0.05 vs基线<sup>*</sup>P &lt; 0.05 vs对照组。</p><p>该结果显示，应用托伐普坦和人血白蛋白联合治疗肝硬化顽固性腹水，与治疗前相比，大约在14天时患者的血钠水平明显上升，腹围明显减小，尿量明显增多，差别具有统计学意义(<sup>Δ</sup>P &lt; 0.05)，另外，相比较对照组，同样在大约14天开始患者的血钠水平明显上升，腹围减小，尿量明显增多(<sup>*</sup>P &lt; 0.05)。说明托伐普坦和人血白蛋白联合治疗肝硬化顽固性腹水的效果可能较单纯应用常规治疗方法更为显著。</p><p>2.) 比较两组不良反应发生率</p><p>两组患者均未出现明显不良反应，实验组2例出现口干，对照组3例出现口干，症状较轻，为托伐普坦较常见的副作用，对本研究无影响。</p></sec><sec id="s8"><title>4. 讨论</title><p>肝硬化顽固性腹水的形成机制是复杂和多方面的，主要包括低蛋白血症、淋巴回流障碍，以及门静脉高压引起的内脏血管扩张，导致肾素–血管紧张素–醛固酮系统激活，血管紧张素激活后收缩肾脏血管，导致水钠潴留等 [<xref ref-type="bibr" rid="hanspub.37930-ref3">3</xref>]。主要治疗方法包括应用限制钠盐输入、使用利尿剂、补充白蛋白、腹腔穿刺大量放液、经颈静脉肝内门腔静脉分流术(TIPS)等等。大量应用利尿剂常常引起低钾血症、诱发肝肾综合征、肝昏迷等并发症，而TIPS由于削弱了肝脏的解毒作用，毒素的增加可大大提高发生肝昏迷的风险 [<xref ref-type="bibr" rid="hanspub.37930-ref4">4</xref>]。托伐普坦作为新一代口服的选择性血管加压素V2受体拮抗剂，近年来对于肝硬化难治性腹水的应用得到广泛关注。它能够有效阻断肾集合管V2受体，在不影响尿钠或钾排泄的前提下增加自由水的排除，成为治疗低钠型肝硬化难治性腹水的理想用药 [<xref ref-type="bibr" rid="hanspub.37930-ref5">5</xref>]。而人血白蛋白可有效提高血浆胶体渗透压，从而减少腹水的生成。我们的研究表明，应用托伐普坦联合人血白蛋白治疗肝硬化难治性腹水，显效较早，在大约用药14天后可观察到明显效果，且安全性与常规治疗相比并无明显区别。因此，该研究为肝硬化难治性腹水的治疗提供了新的思路，具有广泛临床应用前景。</p></sec><sec id="s9"><title>文章引用</title><p>潘月飞,王雪省,乔富平. 托伐普坦治疗联合人血白蛋白肝硬化顽固性腹水的临床观察Clinical Observation of Tolvaptan in Combination with Human Albumin in Treating Refractory Ascites Due to Liver Cirrhosis[J]. 医学诊断, 2020, 10(03): 173-176. https://doi.org/10.12677/MD.2020.103028</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.37930-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">中华医学会肝病学分会、感染病学分会. 慢性乙型肝炎防治指南[J]. 中华实验和临床感染病杂志: 电子版, 2011(1): 79-100.</mixed-citation></ref><ref id="hanspub.37930-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">中华医学会肝病学分会. 肝硬化腹水及相关并发症的诊疗指南[J]. 中华实验和临床感染病杂志: 电子版, 2017, 11(5): 417-432.</mixed-citation></ref><ref id="hanspub.37930-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">阚晓, 崔蕾, 潘家超, 等. 托伐普坦治疗肝硬化失代偿期患者稀释性低钠血症[J]. 中华传染病杂志, 2013, 31(11): 658-662.</mixed-citation></ref><ref id="hanspub.37930-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">郭皓, 吴利娟, 金哲, 等. 血管加压素V2受体拮抗剂托伐普坦治疗肝硬化并低钠血症和肝性水肿的系统评价[J]. 世界华人消化杂志, 2016, 24(6): 938-946.</mixed-citation></ref><ref id="hanspub.37930-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">European Association for the Study of the Liver. (2010) EASL Clinical Practice Guidelines on the Management of Ascites, Spontaneous Bacterial Peritonitis, and Hepatorenal Syndrome in Cirrhosis. Journal of Hepa-tology, 53, 397-417.&lt;br&gt;https://doi.org/10.1016/j.jhep.2010.05.004</mixed-citation></ref></ref-list></back></article>